Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
23-26 March, 2026
Global ChemShowGlobal ChemShow
Not Confirmed
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Not Confirmed
Not Confirmed
12-15 January, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
DCAT Week
Not Confirmed
Contact SupplierDCAT Week
Industry Trade Show
Not Confirmed
23-26 March, 2026
Global ChemShowGlobal ChemShow
Industry Trade Show
Not Confirmed
19-20 December, 2025
BIO Partnering at JPMBIO Partnering at JPM
Industry Trade Show
Not Confirmed
12-15 January, 2026
Digital content
NEWS #PharmaBuzz
25 Nov 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-achievement-of-milestone-under-antibody-drug-conjugate-collaboration-with-mitsubishi-tanabe-pharma-corporation-302625157.html
23 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-updated-phase-1-monotherapy-data-on-gv20-0251-at-the-asco-annual-meeting-2025-302463357.html
27 Mar 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-collaboration-agreement-with-mitsubishi-tanabe-pharma-corporation-to-develop-novel-antibody-drug-conjugates-302411169.html
16 Sep 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-presents-promising-phase-1-monotherapy-data-on-novel-checkpoint-inhibitor-gv20-0251-at-esmo-congress-2024-302247149.html
21 Aug 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-clinical-data-on-gv20-0251-at-the-esmo-congress-2024-302225841.html
24 Apr 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-publication-in-cell-highlighting-the-discovery-of-igsf8-as-an-innate-immune-checkpoint-and-cancer-immunotherapy-target-302126064.html
Drugs in Development
Details:
The collaboration aims to develop an undisclosed antibody-drug conjugate for cancer treatment.
Lead Product(s): Undisclosed,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Antibody-drug Conjugate
Sponsor: Mitsubishi Tanabe Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration November 25, 2025
Lead Product(s) : Undisclosed,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
Gv20 Therapeutics Achieves Milestone with Mitsubishi Tanabe Pharma in ADC Collaboration
Details : The collaboration aims to develop an undisclosed antibody-drug conjugate for cancer treatment.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
November 25, 2025
Details:
GV20-0251 is a Other Large Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Hepatocellular.
Lead Product(s): GV20-0251,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Recipient: West China Hospital
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 06, 2025
A Study of GV20-0251 in Advanced or Refractory Solid Tumors
Details : GV20-0251 is a Other Large Molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Carcinoma, Hepatocellular.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 06, 2025
Details:
GV20-0251 is a Other Large Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): GV20-0251,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable July 17, 2025
Lead Product(s) : GV20-0251,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of GV20-0251 in Participants with Solid Tumor Malignancies
Details : GV20-0251 is a Other Large Molecule drug candidate, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 17, 2025
Details:
Under this collaboration, MTPC will leverage GV20's antibodies, which are specifically directed against novel tumor antigen targets discovered through STEAD AI platform, to generate ADCs.
Lead Product(s): Undisclosed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Discovery PlatformProduct Type: Antibody-drug Conjugate
Sponsor: Mitsubishi Tanabe Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration March 26, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery Platform
Partner/Sponsor/Collaborator : Mitsubishi Tanabe Pharma
Deal Size : Undisclosed
Deal Type : Collaboration
GV20, Mitsubishi Tanabe Partner to Develop Novel Antibody-Drug Conjugates
Details : Under this collaboration, MTPC will leverage GV20's antibodies, which are specifically directed against novel tumor antigen targets discovered through STEAD AI platform, to generate ADCs.
Product Name : Undisclosed
Product Type : Antibody-drug Conjugate
Upfront Cash : Undisclosed
March 26, 2025
Details:
Under the agreement, GV20 will evaluate its lead program GV20-0251, an antibody targeting immune checkpoint IGSF8, in combination with Merck's anti-PD-1, KEYTRUDA, for advanced tumors.
Lead Product(s): GV20-0251,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 18, 2024
Lead Product(s) : GV20-0251,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
GV20 Collaborates to Evaluate GV20-0251 with KEYTRUDA®
Details : Under the agreement, GV20 will evaluate its lead program GV20-0251, an antibody targeting immune checkpoint IGSF8, in combination with Merck's anti-PD-1, KEYTRUDA, for advanced tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
April 18, 2024
Details:
GV20-025 is the first ever AI-designed antibody against an AI-predicated target, which is being evaluated for the treatment of patients with solid tumors.
Lead Product(s): GV20-0251,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2024
GV20 Therapeutics Presents Preclinical Data on GV20-0251 for Solid Tumors at AACR 2024
Details : GV20-025 is the first ever AI-designed antibody against an AI-predicated target, which is being evaluated for the treatment of patients with solid tumors.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 08, 2024
Details:
GV20-0251 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Lead Product(s): GV20-0251,Inapplicable
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Merck & Co
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 30, 2022
Lead Product(s) : GV20-0251,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : GV20-0251 is a Other Large Molecule drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Neoplasms.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 30, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Share 
